We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.
- Authors
De Castro, J.; González-Larriba, J.; Vázquez, S.; Massutí, B.; Sanchez-Torres, J.; Dómine, M.; Garrido, P.; Calles, A.; Artal, A.; Collado, R.; García, R.; Sereno, M.; Majem, M.; Macías, J.; Juan, O.; Gómez-Codina, J.; Hernández, B.; Lázaro, M.; Ortega, A.; Cobo, M.
- Abstract
Background/Aim: First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. Patients and methods: This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months. Results: Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies. Conclusion: Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.
- Publication
Clinical & Translational Oncology, 2017, Vol 19, Issue 2, p219
- ISSN
1699-048X
- Publication type
Article
- DOI
10.1007/s12094-016-1527-8